This study is exploring a new way to treat people with HIV-1 who already have very low virus levels (under 50 copies/mL). It compares taking a new tablet once a week with the regular daily medicines that people usually take. The new tablet combines two medicines: **islatravir** and **lenacapavir**. The study wants to see if the new tablet works just as well after 48 weeks.

To join, you should have had low virus levels for at least 6 months and be on a stable treatment. You shouldn't have had any major problems with your virus treatment before or have certain infections like hepatitis or tuberculosis.

• **Timeframe:** The study goes on for 48 weeks.
• **Visits:** Regular check-ups are required.
• **Risks:** There may be unknown risks with the new tablet.